Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : KDUS, who knows this company? -- Ignore unavailable to you. Want to Upgrade?

To: SVogel who wrote (77)	1/30/1998 7:47:00 PM
From: scaram(o)uche	Read Replies (2) \| Respond to of 117

Steve: The outcome of the SIBI versus KDUS litigation would have virtually no effect on SIBI if the decision went against them. It could put KDUS out of business (it wouldn't, but it would cost them dearly) if SIBI won, however. Next time you talk to Ms. Levine, why not ask for the current justification of the KDUS stance? Did the litigation have any role in kissing Levin goodbye? I like the company. However, given the price performance of the stock and the sudden CEO croak, one might want to consider that something major went wrong with the business plan. A portion of a recent press release relating to the "629" patent (5,401,629) follows this note. Up-front, maintenance, and royalties........ SIBIA Neurosciences, Inc.'s Drug Discovery Technology Sublicensed by Aurora Biosciences Corporation to Eli Lilly & Co. LA JOLLA, Calif., Jan. 14 /PRNewswire/ -- SIBIA Neurosciences, Inc. (Nasdaq: SIBI) today announced that Aurora Biosciences Corporation has sublicensed to Eli Lilly and Company SIBIA's patented transcription-based assay (TBA) technology for drug screening and drug discovery. As a result of this sublicense, SIBIA will receive an up-front payment and annual maintenance payments, as well as future royalties. Aurora sublicensed the SIBIA technologies to Lilly for use in conjunction with Aurora's drug screening technologies. Pursuant to a cross licensing agreement signed between SIBIA and Aurora in December 1996, SIBIA and Aurora both have certain rights to use and sublicense certain of each other's patents and assay technologies. SIBIA's TBA patents (U.S. Patent Nos. 5,401,629 and 5,436,128) cover cell- based assays that employ promoter-reporter gene constructs to measure the functional activity of test compounds on cell-surface proteins in living cells. SIBIA Neurosciences, Inc.'s Drug Discovery Technology Sublicensed by Aurora Biosciences Corporation to Eli Lilly & Co. LA JOLLA, Calif., Jan. 14 /PRNewswire/ -- SIBIA Neurosciences, Inc. (Nasdaq: SIBI) today announced that Aurora Biosciences Corporation has sublicensed to Eli Lilly and Company SIBIA's patented transcription-based assay (TBA) technology for drug screening and drug discovery. As a result of this sublicense, SIBIA will receive an up-front payment and annual maintenance payments, as well as future royalties. Aurora sublicensed the SIBIA technologies to Lilly for use in conjunction with Aurora's drug screening technologies. Pursuant to a cross licensing agreement signed between SIBIA and Aurora in December 1996, SIBIA and Aurora both have certain rights to use and sublicense certain of each other's patents and assay technologies. SIBIA's TBA patents (U.S. Patent Nos. 5,401,629 and 5,436,128) cover cell- based assays that employ promoter-reporter gene constructs to measure the functional activity of test compounds on cell-surface proteins in living cells. (snip)